ArticleAmerican journal of respiratory and critical care medicine2019
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 68 citations in OpenAlex.
- Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung).ESMO open · 2026Trial
- Computational Phosphosite-Specific Network Analysis of YES1 Y426 Reveals Cancer-Associated Phosphorylation Patterns.Proteomes · 2026Article
- The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations.EMBO molecular medicine · 2025Article
- Research on the regulatory effects and mechanisms of YES1 on apoptosis and autophagy in cervical cancer cells.Discover oncology · 2025Article
- Review
- Molecular Pharmacology of Dasatinib Provides Unique Insights into the Mechanistic Basis of Success and Failure of Targeted Cancer Therapy.ACS pharmacology & translational science · 2025Review
- ACSL3 regulates breast cancer progressionCancer biology & medicine · 2024Article
- DDCM: A Computational Strategy for Drug Repositioning Based on Support-Vector Regression Algorithm.International journal of molecular sciences · 2024Article
- YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.Archives of toxicology · 2024Article
- Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.International journal of molecular sciences · 2024Review
- Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection?Translational lung cancer research · 2023Article
- Modern therapies of nonsmall cell lung cancer.Journal of applied genetics · 2023Review
- A renaissance for YES in cancer.Oncogene · 2023Review
- Review
- Role of YES1 signaling in tumor therapy resistance.Cancer innovation · 2023Review
- CRISPR-Cas9-mediated gene therapy in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.Molecular biology reports · 2023Review
- Recent progress in targeted therapy for non-small cell lung cancer.Frontiers in pharmacology · 2023Review
- Combining bioinformatics and machine learning algorithms to identify and analyze shared biomarkers and pathways in COVID-19 convalescence and diabetes mellitus.Frontiers in endocrinology · 2023Article
- A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.Current oncology (Toronto, Ont.) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
28 authors at 10 institutions in 2 countries.
Irati GarmendiaProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.ORCID 0000-0001-7124-6137
María J PajaresProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.ORCID 0000-0003-3149-8959
Francisco Hermida-PradoCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Daniel AjonaProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Cristina BértoloProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Cristina SainzProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Amaya LavínProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Ana B RemírezProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Karmele ValenciaProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Haritz MorenoProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Irene FerrerCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Carmen BehrensDepartment of Translational Molecular Pathology and.
Myriam CuadradoCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Luis Paz-AresCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Xosé R BusteloCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Ignacio Gil-BazoCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Daniel AlamedaProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Fernando LecandaProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Alfonso CalvoProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Enriqueta FelipOncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; and.
Montse Sánchez-CéspedesCancer Epigenetics and Biology Program, Genes and Cancer Group, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Barcelona, Spain.
Ignacio I WistubaDepartment of Translational Molecular Pathology and.
Rocio Granda-DiazCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Juan Pablo RodrigoCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Juana María García-PedreroCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Ruben PioProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Luis M MontuengaProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.ORCID 0000-0002-8739-1387
Jackeline AgorretaProgram in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain.
Centro de Investigación Biomédica en Red de Cáncer · ESUniversidad de Navarra · ESUniversidad de Oviedo · ESConsejo Superior de Investigaciones Científicas · ESThe University of Texas MD Anderson Cancer Center · USBellvitge University Hospital · ESClinica Universidad de Navarra · ESSpanish National Cancer Research Centre · ESUniversidad Complutense de Madrid · ESVall d'Hebron Hospital Universitari · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
A549 CellsAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationCRISPR-Cas SystemsDasatinibGene AmplificationGene Knockdown TechniquesGene Knockout TechniquesHumansLung NeoplasmsMicePrognosisProto-Oncogene MasAntineoplastic AgentsDasatinibMAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins c-yesTOR Serine-Threonine KinasesYES1 protein, humandasatiniblung cancerpredictive biomarkerSrc family kinasesYES1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.